drugset / Trial / NCT07274813
A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors
Non-randomizedSingle-groupOpen-labelOther
Summary
This study is an open-label first-in-human phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HLX37 in patients with advanced/metastatic solid tumors.
Timeline
- Start
- 2025-12-29
- Primary completion
- 2027-03-30
- Completion
- 2028-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HLX37 | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | HLX37 | Monoclonal antibody | 20 mg/kg | Intravenous |
| Subject | HLX37 | Monoclonal antibody | 30 mg/kg | Intravenous |